< 1 minute read
Dec. 20, 2021

Tepotinib: a KGaA MET Kinase Inhibitor

tepotinib

oral MET kinase inhibitor approved for clinical use in NSCLC internal HTS and SBDD Clinical Cancer Research Merck KGaA

drughunter.com
Drug Hunter Team

The Merck KGaA MET kinase inhibitor, tepotinib, was approved earlier this year for METex14 positive NSCLC patients, and is administered once-daily in contrast to capmatinib, which was approved in 2020. Both molecules were approved based on small numbers of patients (tepotinib pivotal trial: NCT02864992) due to the significance of the [...]

Loading...

twitterlinkedinemail

Other molecules you may be interested in